Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.

Biotechnology

Olema Oncology

Sean P. Bohen

Kristin Lowland Lanzi

Peter Kushner

Geoffrey Mogilner

Sasha Austin

Kamesh Kuchimanchi

Jim Zhang

Kristin Lanzi

David C. Myles

Naseem Zojwalla

Julie Dexter

Shane Kovacs

The Clinical and Pharmacology team at Olema Oncology is responsible for designing, implementing, and managing clinical trials and pharmacology studies to evaluate the safety, efficacy, and pharmacokinetics of investigational therapies like OP-1250. This team ensures compliance with regulatory standards, analyzes clinical data, and communicates findings to support the advancement of novel treatments for women’s cancers. Their multidisciplinary expertise spans pre-clinical and clinical development, quality management, medical affairs, and data management.

Clinical and Pharmacology

Leadership Team

Clinical Development Team

Clinical and Pharmacology

About

Team members

Other teams at Olema Oncology

Leadership Team

Clinical Development Team